How long should dual antiplatelet therapy continue after PCI?
After PCI with a drug-eluting stent for acute coronary syndrome, the default is 12 months of dual antiplatelet therapy (DAPT: aspirin plus a P2Y12 inhibitor), with duration individualised to ischaemic and bleeding risk. The 2023 ESC acute coronary syndrome guideline recommends 12 months as the standard but endorses shorter or de-escalated regimens in patients at high bleeding risk [1].
In patients at high bleeding risk, abbreviating DAPT is supported by MASTER DAPT: stopping DAPT at 1 month (continuing single antiplatelet therapy) was non-inferior for net adverse clinical and ischaemic events and reduced major or clinically relevant bleeding compared with continuing DAPT for at least 3 additional months [2].
Conversely, selected patients with high ischaemic and low bleeding risk may benefit from extended DAPT beyond 12 months. Duration should be a shared, risk-stratified decision rather than a fixed rule [1, 2].
- Optimal duration is a risk trade-off (ischaemia vs bleeding), not a single fixed number; recommendations differ for chronic coronary syndrome/elective PCI versus ACS.
- MASTER DAPT specifically addresses high-bleeding-risk patients and may not generalise to lower-risk populations.
2023 ESC Guidelines for the management of acute coronary syndromes
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk (MASTER DAPT)
Illustrative example of a CliniAtlas reading, for professional reference only. Verify as a healthcare professional to ask your own questions against live sources.